{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:37:33Z","timestamp":1792517853687,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background aim<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR)-T cell therapy is highly effective for relapsed\/refractory multiple myeloma (R\/R MM). Prolonged hematological toxicity (PHT) is a significant adverse event that adversely affects patient outcomes; however, specific predictive tools are lacking. Our prior study demonstrated that baseline Controlling Nutritional Status (CONUT) affects the prognosis of R\/R MM patients receiving CAR-T cell therapy. We aimed to develop and validate a nomogram based on CONUT score for the early prediction of PHT after CAR-T cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 302 consecutive patients with R\/R MM who received CAR-T cell therapy. Patients were randomly allocated to training and validation cohorts (7:3 ratio). The primary endpoint was prolonged grade 3\/4 neutropenia &amp;gt;28 days; predictors were identified using logistic regression. The model's performance was assessed by the area under the curve (AUC), calibration curves, and decision curve analysis (DCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Multivariable analysis confirmed four independent predictors for the primary endpoint (prolonged grade 3\/4 neutropenia &amp;gt;28 days): high tumor burden (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.013), ferritin (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002), interferon-\u03b3 (IFN-\u03b3,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.018), and CONUT score (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.011). The nomogram built on these factors demonstrated a bias-corrected AUC of 0.815 in the training cohort, which was superior to the CAR-HEMATOTOX model (AUC: 0.706,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). The predictive performance remained robust in the internal validation cohort (AUC: 0.824). The calibration curves showed good agreement between prediction and observation, and DCA confirmed the clinical utility of the model. The nomogram also exhibited excellent discriminative ability for predicting a composite PHT endpoint (AUC: 0.821,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.417).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We developed a validated nomogram that incorporates the baseline CONUT score and key clinical variables (e.g., tumor burden, ferritin, IFN-\u03b3) to effectively predict PHT risk in R\/R MM patients after CAR-T cell therapy, thereby facilitating early risk stratification and guiding personalized management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1729151","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:45Z","timestamp":1771824465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Construction and validation of a nutritional status (CONUT)-based nomogram for predicting prolonged hematological toxicity in relapsed\/refractory multiple myeloma after CAR-T cell therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Peng","family":"Xu","sequence":"first","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ying","family":"Duan","sequence":"additional","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Wen","family":"Feng","sequence":"additional","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Wang","sequence":"additional","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Ming","family":"Qi","sequence":"additional","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yu","family":"Li","sequence":"additional","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yun","family":"Wu","sequence":"additional","affiliation":[{"name":"Blood Disease Institute, Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou","place":["Jiangsu, China"]},{"name":"Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","article-title":"Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"8","author":"Ebraheem","year":"2024","journal-title":"Blood Adv."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"125","author":"Nooka","year":"2015","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"123464","DOI":"10.1016\/j.biomaterials.2025.123464","article-title":"CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma","volume":"324","author":"Li","year":"2026","journal-title":"Biomaterials."},{"key":"B6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1499590","DOI":"10.3389\/fimmu.2025.1499590","article-title":"CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy","volume":"16","author":"Yu","year":"2025","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e006406","DOI":"10.1136\/jitc-2022-006406","article-title":"Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT transplant complications working party","volume":"11","author":"Penack","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1019548","DOI":"10.3389\/fimmu.2022.1019548","article-title":"Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/advances\/nmaa102","article-title":"Prognostic potential of the preoperative controlling nutritional status (CONUT) score in predicting survival of patients with cancer: a systematic review","volume":"12","author":"Kheirouri","year":"2021","journal-title":"Adv Nutr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.3390\/nu15245068","article-title":"Nutritional management of oncological symptoms: a comprehensive review","volume":"15","author":"Garutti","year":"2023","journal-title":"Nutrients"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/jpen.2321","article-title":"Value of the controlling nutritional status score in predicting the prognosis of patients with lung cancer: a multicenter, retrospective study","volume":"46","author":"Liu","year":"2022","journal-title":"J Parenter Enteral Nutr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"952802","DOI":"10.3389\/fimmu.2022.952802","article-title":"Prognostic impact of the controlling nutritional status score in patients with hematologic malignancies: a systematic review and meta-analysis","volume":"13","author":"Lu","year":"2022","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1517223","DOI":"10.3389\/fonc.2025.1517223","article-title":"Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis","volume":"15","author":"Jin","year":"2025","journal-title":"Front Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1654407","DOI":"10.3389\/fnut.2025.1654407","article-title":"Nutritional status indices on the prognosis of patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy","volume":"12","author":"Xu","year":"2025","journal-title":"Front Nutr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1111\/jcmm.17930","article-title":"Prolonged haematologic toxicity in CAR-T-cell therapy: a review","volume":"27","author":"Liu","year":"2023","journal-title":"J Cell Mol Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am J Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1139559","DOI":"10.3389\/fimmu.2023.1139559","article-title":"Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"1","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/blood-2012-05-432906","article-title":"Interferon-gamma impairs proliferation of hematopoietic stem cells in mice","volume":"121","author":"de Bruin","year":"2013","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2018.10.003","article-title":"Interleukin-18 plays a dispensable role in murine and likely also human bone marrow failure","author":"Wu","year":"2019","journal-title":"Exp Hematol"},{"key":"B31","first-page":"38","article-title":"CONUT: a tool for controlling nutritional status First validation in a hospital population","volume":"20","author":"Ignacio de Ul\u00edbarri","year":"2005","journal-title":"Nutr Hosp"},{"key":"B32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00277-019-03844-2","article-title":"Clinical impact of the CONUT score in patients with multiple myeloma","volume":"99","author":"Okamoto","year":"2020","journal-title":"Ann Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/life15020289","article-title":"Optimizing autologous stem cell transplantation in multiple myeloma: the significance of pre-transplant controlling nutritional status score","volume":"15","author":"\u00d6zkan","year":"2025","journal-title":"Life"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1729151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:46Z","timestamp":1771824466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1729151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":33,"alternative-id":["10.3389\/fnut.2026.1729151"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1729151","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1729151"}}